Nivagen Pharmaceuticals, Inc.

Nivagen Pharmaceuticals, Inc. is engaged in developing, manufacturing, and marketing pharmaceutical products, including generics and specialty drugs, with a focus on sterile injectables for healthcare providers in North America. Founded in 2009, Nivagen Pharmaceuticals, Inc. operates out of Sacramento, US, specializing in the pharmaceuticals sector.

In January 2026, PAI Pharma, a portfolio company of Olympus Partners, acquired Nivagen Pharmaceuticals, Inc. from Telegraph Hill Partners. The company's core offerings include sterile injectables in various formats such as IV bags, vials, pre-filled syringes (PFS), and cartridges, which cater to healthcare providers and institutional clients in the North American market. Nivagen also provides 503B compounding services, ensuring compliance with regulatory standards while meeting the needs of hospitals and clinics for customized medication solutions.

The company’s state-of-the-art sterile manufacturing facility in California enables it to produce a variety of dosage forms, including ophthalmic products, thereby addressing critical healthcare needs in the marketplace. Nivagen’s commitment to delivering high-quality, affordable products positions it effectively to serve a broad client base, including hospitals, outpatient facilities, and pharmacy networks across the United States and Canada. Nivagen Pharmaceuticals operates on a revenue model that includes direct sales of its pharmaceutical products to healthcare institutions, wholesalers, and pharmacy networks. The company engages in business-to-business transactions with its clients, who typically place orders for bulk supplies of generic prescription drugs and over-the-counter products, as well as custom compounding services.

Nivagen's revenue is generated from the sale of its flagship products, including sterile injectables and specialized formulations that meet specific patient needs. While the company’s pricing structure is tailored to the competitive landscape, it typically establishes contracts with institutional clients that define terms for product pricing, volume discounts, and delivery schedules. This transactional framework supports Nivagen’s goal of providing high-quality pharmaceutical solutions while maintaining strong relationships with its customer base in the North American market. Nivagen Pharmaceuticals plans to leverage its recent funding of USD 16 mn raised in May 2020 to drive the development of new pharmaceutical products and expand its market reach.